Obesity
Explore facts and recommendations for pharmacological treatments for obesity.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Subcutaneous Semaglutide vs Placebo for Weight Management in Combination with IBT (STEP 3)
This video discusses STEP 3, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-blind, multicenter trial conducted in 611 adult patients with obesity or overweight and at least 1 weight-related comorbidity in the US
Subcutaneous Semaglutide 2.4mg vs Subcutaneous Semaglutide 1.0mg and Placebo for Weight Management in Adults with Type 2 Diabetes (STEP 2)
This video discusses STEP 2, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-dummy, double-blind, multicenter, multinational trial conducted in 1210 adult patients with obesity or overweight and type 2 diabetes.
Semaglutide injection Mode of Action in Obesity
This video discusses the mechanism of action of the subcutaneous semaglutide injection indicated for Obesity.
Current Recommendations for Weight-Loss Medications as Part of Obesity Management (IME content)
Snapshot of why medication is a powerful tool in obesity management.
Subcutaneous Semaglutide vs Placebo for Weight Management in Adults (STEP 1)
This video discusses the STEP 1 trial, which was a phase 3a, 68-week, randomized, placebo-controlled, double-blind, multinational trial conducted in 1961 adult patients with obesity, or overweight with at least 1 weight-related comorbidity.
STEP 1 Clinical Trial: Weight Management with Semaglutide Injection
Results of a 68-week trial comparing weight loss while receiving semaglutide injection or placebo in 1961 adults with obesity or overweight.
STEP 2 Clinical Trial: Weight Management with Semaglutide Injection in Adults with Type 2 Diabetes
Findings of a 68-week trial comparing semaglutide injection 2.4mg vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.
STEP 3 Clinical Trial: Weight Management with Semaglutide Injection and Intensive Behavioral Therapy (IBT)
Outcomes of a 68-week trial comparing semaglutide injection vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.
Continuing Education
Find accredited opportunities in obesity education.
Obesity
Obesity
Looking for additional resources?
Explore other libraries or search the Exchange.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
